{"id":"cohort-1-neo-adjuvant","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"1-5%","effect":"Colitis"},{"rate":"5-10%","effect":"Hypothyroidism"},{"rate":"1-5%","effect":"Hyperthyroidism"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"10-20%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL258020","moleculeType":"Small molecule","molecularWeight":"1163.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially slows or stops cancer progression.","oneSentence":"This drug targets the PD-1 receptor to inhibit cancer cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:26:53.955Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable or metastatic melanoma"},{"name":"Locally advanced or metastatic non-small cell lung cancer"},{"name":"Locally advanced or metastatic renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT03313206","phase":"PHASE2","title":"Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-05-28","conditions":"Head and Neck Mucosal Melanomas","enrollment":60},{"nctId":"NCT06630130","phase":"PHASE2","title":"Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer","status":"RECRUITING","sponsor":"Jeeyun Lee","startDate":"2025-01-22","conditions":"Stomach Neoplasms","enrollment":50},{"nctId":"NCT05088395","phase":"NA","title":"Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-05-19","conditions":"Cancer","enrollment":2050},{"nctId":"NCT05142189","phase":"PHASE1","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2022-06-17","conditions":"Non-Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT05839912","phase":"NA","title":"Excision of Lymph Node Trial (EXCILYNT) (Mel69)","status":"RECRUITING","sponsor":"Craig L Slingluff, Jr","startDate":"2023-09-06","conditions":"Melanoma","enrollment":66},{"nctId":"NCT05570422","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01","status":"NOT_YET_RECRUITING","sponsor":"Kortuc, Inc.","startDate":"2025-12-01","conditions":"Cervical Cancer","enrollment":70},{"nctId":"NCT01088789","phase":"PHASE2","title":"Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-04-20","conditions":"Pancreatic Cancer","enrollment":71},{"nctId":"NCT04467593","phase":"NA","title":"Safety Study of Whole Body Hyperthermia for Advanced Cancer","status":"COMPLETED","sponsor":"ElmediX","startDate":"2021-07-28","conditions":"Advanced Cancer, Pancreatic Cancer Metastatic","enrollment":16},{"nctId":"NCT01748149","phase":"EARLY_PHASE1","title":"Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-04-29","conditions":"Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas","enrollment":40},{"nctId":"NCT07004244","phase":"PHASE1","title":"Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-06-05","conditions":"Malignant Tumors","enrollment":20},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT02917421","phase":"PHASE1, PHASE2","title":"Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12-19","conditions":"Breast Cancer","enrollment":88},{"nctId":"NCT04025541","phase":"NA","title":"Analysis of Circulating Tumor Markers in Blood","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2018-05-29","conditions":"Cancer, Breast Cancer, Sarcoma","enrollment":992},{"nctId":"NCT03387761","phase":"PHASE1","title":"Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2018-01-15","conditions":"Urothelial Carcinoma","enrollment":54},{"nctId":"NCT04289805","phase":"PHASE4","title":"Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2019-02-25","conditions":"Breast Neoplasm Malignant Female","enrollment":96},{"nctId":"NCT02089269","phase":"","title":"Tumor Registry Pancreatic Cancer","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2013-12","conditions":"Pancreas Cancer","enrollment":2325},{"nctId":"NCT05034887","phase":"PHASE2","title":"Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-01-31","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT01542021","phase":"NA","title":"Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-02-24","conditions":"Prostate Cancer, Prostatic Adenocarcinoma","enrollment":41},{"nctId":"NCT03532451","phase":"PHASE1","title":"Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2019-03-22","conditions":"Bladder Cancer","enrollment":43},{"nctId":"NCT01595321","phase":"PHASE2","title":"Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-10-29","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT03924466","phase":"PHASE2","title":"Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2019-04-01","conditions":"Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas","enrollment":55},{"nctId":"NCT02977052","phase":"PHASE2","title":"Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-11-24","conditions":"Malignant Melanoma Stage III","enrollment":186},{"nctId":"NCT06032975","phase":"","title":"PRO for Fighting FT in Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-10-30","conditions":"Ovarian Cancer","enrollment":240},{"nctId":"NCT02938624","phase":"PHASE1","title":"Anti PD-1 Neo-adjuvant Treatment for NSCLC","status":"COMPLETED","sponsor":"Jair Bar, M.D., Ph.D.","startDate":"2017-01-07","conditions":"Non Small Cell Lung Carcinoma, Stage I, Stage II","enrollment":28},{"nctId":"NCT02520128","phase":"NA","title":"A Study of IMRT in Primary Bone and Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2016-03","conditions":"Soft Tissue Sarcoma, Adult, Ewing Sarcoma, Bone Sarcoma","enrollment":191},{"nctId":"NCT00617942","phase":"PHASE2","title":"Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer","status":"COMPLETED","sponsor":"William Sikov MD","startDate":"2008-02","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT03166254","phase":"PHASE1","title":"Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2019-04-30","conditions":"Non Small Cell Lung Cancer, NSCLC, Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT01229644","phase":"PHASE2","title":"Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas","status":"TERMINATED","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2011-04","conditions":"Glioma","enrollment":10},{"nctId":"NCT00365872","phase":"PHASE2","title":"External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2006-05","conditions":"Soft Tissue Sarcoma","enrollment":17},{"nctId":"NCT00305669","phase":"PHASE1","title":"GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-07","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT00520091","phase":"PHASE2","title":"Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2005-03","conditions":"Esophageal Cancer","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abraxane (nab-paclitaxel), Herceptin (trastuzumab) and carboplatin"],"phase":"phase_2","status":"active","brandName":"Cohort 1 neo-adjuvant","genericName":"Cohort 1 neo-adjuvant","companyName":"William Sikov MD","companyId":"william-sikov-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Unresectable or metastatic melanoma, Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic renal cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}